Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• Bristol-Myers Squibb recently reported third-quarter earnings that significantly exceeded market expectations, posting $1.35 in earnings per share against a consensus estimate of $1.10, while revenue of $13.07 billion also surpassed the projected $12.72 billion, demonstrating strong operational performance and profitability with a net margin of 18.47%.
• The company offers an attractive income stream for investors with a current dividend yield of 4.06%, supported by a recent quarterly dividend payment of $0.63 per share, which provides a steady cash flow return that is competitive within the pharmaceutical sector.
• Bristol-Myers Squibb is trading at a current stock price of $62.42, which is below the average analyst price target of $65.46, suggesting potential upside as the stock has recently crossed above its 50-day moving average, indicating improving short-term momentum.
• The company's growth portfolio, which drives 57% of total revenues, is gaining traction with key brands like Camzyos showing sustained efficacy in new 56-week Phase 3 pediatric data, helping to offset potential declines in legacy drugs and support long-term growth.
• Bristol-Myers Squibb has a low beta of 0.20, meaning its stock price is significantly less volatile than the overall market, making it a defensive investment option that may provide stability during periods of broader market uncertainty.